Newsfiscal.ai
Artiva Biotherapeutics Discontinues Development of Lead Candidate AlloNK and Initiates Strategic Review
· Published
Article summary
Artiva Biotherapeutics has decided to halt the development of its lead product candidate, AlloNK, and is exploring strategic alternatives to maximize stockholder value.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…